| Document |
Document Title |
|
WO/2023/183520A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2023/183607A1 |
Described herein are compounds or conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading c...
|
|
WO/2023/180388A1 |
The present invention provides a series of 2,4- dioxotetrahydropyrimidinyl derivatives that bind cereblon, and their application as degrons in PROTACs. Androgen receptor PROTACs containing the 2,4-dioxotetrahydropyrimidinyl containing de...
|
|
WO/2023/180964A1 |
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...
|
|
WO/2023/179703A1 |
Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
|
|
WO/2023/179629A1 |
The present invention relates to a substituted bridged ring inhibitor, and to a preparation method therefor and application thereof. Specifically, the compound of the present invention has the structure shown in a formula (A0), and furth...
|
|
WO/2023/183540A1 |
Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
|
|
WO/2023/183601A1 |
This disclosure features methods for preparing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that inhibit epidermal growth factor receptor (EGFR, E...
|
|
WO/2023/179542A1 |
The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
|
|
WO/2023/183919A1 |
Described herein are compounds of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as IKZF2 degraders) in treating or preventing diseases or disorders.
|
|
WO/2023/183613A2 |
The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as...
|
|
WO/2023/182835A1 |
The present invention relates to a novel organic compound and an organic electroluminescent element using same, and more specifically, to a compound having excellent electron injection and transport capabilities, and an organic electrolu...
|
|
WO/2023/179624A1 |
Disclosed in the present invention are a preparation method for a tricyclic compound, and an intermediate thereof, and specifically disclosed is a method for preparing a compound as shown in formula (I-10) or an optical isomer thereof. T...
|
|
WO/2023/183943A1 |
The present disclosure relates to inhibitors of NLRP3 of Formula (I): (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a...
|
|
WO/2023/175632A1 |
The present invention relates to new solid state forms of (5S,6S,9R)-5-amino-6- (2,3Âdifluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyr
idin-9-yl 4-(2-oxo-2,3-dihydro- 1H-imidazo[4,5-b] pyridin-1-yl)-1-piperidinecarboxylate hemisulf...
|
|
WO/2023/176609A1 |
This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...
|
|
WO/2023/174329A1 |
Providing compounds of Formula (A) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as PKMYT1 inhibitors, pharmaceutical compositions comprising the same, and use thereof in the manufacture ...
|
|
WO/2023/177451A1 |
Disclosed herein are compounds of Formula (I): Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinas...
|
|
WO/2023/178256A1 |
The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib o...
|
|
WO/2023/178099A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/178269A1 |
The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/159688A9 |
Provided herein are compounds (e.g., compounds of Formulae (A-I), (B-I), (C-I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs...
|
|
WO/2023/174314A1 |
Provided is the use of a compound of formula I, a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a metabolite or a prodrug thereof, or a composition thereof in the preparation of a drug for treating alopecia su...
|
|
WO/2023/178285A1 |
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2023/174250A1 |
This disclosure provides compounds containing 4- (aminomethyl) -6- (1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H) -onestructure, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MT...
|
|
WO/2023/174300A1 |
Disclosed in the present invention are a crystal form of a BTK inhibitor, an acid salt thereof, and a crystal form of the acid salt thereof. The crystal form of a compound of formula I in the present invention is a free alkali crystal fo...
|
|
WO/2023/174406A1 |
The present invention relates to a nitrogen-containing heterocyclic derivative EGFR inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (I)...
|
|
WO/2023/174374A1 |
The present disclosure relates to a fused heterocyclic compound, and a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a fused heterocyclic compound shown in general formula (I), a p...
|
|
WO/2023/173136A2 |
Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1...
|
|
WO/2023/173124A1 |
Aspects disclosed herein relate to compositions comprising novel phosphoinositide 3-kinase (PI3K) inhibitors, and methods of making the novel PI3K inhibitors. Further, various aspects relate to one or more methods of treating a disease u...
|
|
WO/2023/169371A1 |
Disclosed in the present invention are a compound having a benzyloxy aryl ether structure, and a preparation method therefor and the use thereof. The structure of the compound having the benzyloxy aryl ether structure is as represented b...
|
|
WO/2023/169535A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit the protein (s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life ...
|
|
WO/2023/168686A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
|
|
WO/2023/173083A1 |
This disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt that inhibits epidermal growth factor receptor (EGER, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These compounds of formu...
|
|
WO/2023/169456A1 |
This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.
|
|
WO/2023/169226A1 |
Provided are substituted tricyclic compounds as PARP inhibitors and the use thereof. The compounds represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L and Cy are defined herein. The compounds of Fo...
|
|
WO/2023/172846A1 |
Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/172667A2 |
The present disclosure provides substituted imidazo[1,5-a]pyridine N-heterocyclic carbene (NHC) ligands, catalyst complexes thereof, and methods using same. The present disclosure further provides synthetic methods of preparing N-heteroc...
|
|
WO/2023/169964A1 |
Use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor The use of pyrazolo[3,4-b]pyridine compounds as nitrification inhibitor.
|
|
WO/2023/169554A1 |
Provided in the present application are a methionine adenosine transferase inhibitor, a pharmaceutical composition containing same, and the use thereof. The compound of the present application has excellent MAT2a enzyme inhibitory activi...
|
|
WO/2023/172921A1 |
The present application provides solid forms and salts of a compound of Formula (I): (I) pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the c...
|
|
WO/2023/169488A1 |
The present application relates to the field of pharmaceutical chemistry, and provides a pharmaceutical combination comprising a pyrido [1,2-a] pyrimidinone compound and an EGFR inhibitor. Specifically, the pharmaceutical combination com...
|
|
WO/2023/169569A1 |
The present disclosure relates to compounds that inhibit IAP (preferably cIAP1, cIAP2 or XIAP) protein, pharmaceutical compositions comprising the same and methods of using the IAP protein inhibitors in the treatment of diseases and cond...
|
|
WO/2023/172663A1 |
The present disclosure encompasses solid state forms of Tolebrutinib and of Tolebrutinib salts, in embodiments crystalline polymorphs of Tolebrutinib and of Tolebrutinib salts, processes for preparation thereof, and pharmaceutical compos...
|
|
WO/2023/170724A1 |
There is provided a novel use of a substituted quinolone compound of the general formula (I), or a pharmaceutically acceptable salt thereof for treatment of cancer. The prepared substituted quinolones with dual anti-inflammation/free rad...
|
|
WO/2023/173016A1 |
The present disclosure relates to diaryl compounds targeting KRAS, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat disease, such as cancer.
|
|
WO/2023/169436A1 |
Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
|
|
WO/2023/169438A1 |
The invention relates to nitrogen-containing heterocyclic compounds as well as a preparation method therefor and the use thereof, in particular to a nitrogen-containing heterocyclic compound represented in general formula (I), or a pharm...
|
|
WO/2023/169547A1 |
A nitrogen-containing heterocyclic compound represented by formula (I-c), or a stereoisomer, a deuterated compound or a pharmaceutically acceptable salt, and a pharmaceutical composition thereof. Also provided is a use of the compound in...
|
|
WO/2023/165504A1 |
Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
|
